Commentary on the CheckMate 9ER clinical trial

Czech version

Authors: I.- Richter ^{1 3}; J. Bartoš ¹; J. Dvořák ²
Authors‘ workplace: Onkologické oddělení, Krajská nemocnice Liberec, a. s. ¹; Onkologická klinika 1. LF UK a FTN Praha ²; Fakulta zdravotnických studií, Technická univerzita Liberec ³
Published in: Klin Onkol 2025; 38(4): 307-309
Category: Short Communication
doi: https://doi.org/10.48095/ccko2025307

Sources

1. Dušek L, Mužík J, Kubásek M et al. Epidemiologie zhoubných nádorů v České republice. [online]. Dostupné z: https: //portal.med.muni.cz/clanek-583-epidemiologie-zhoubnych-nadoru-v-ceske-republice.html.

2. Kaelin WG. The von Hippel-Lindau tumour suppressors protein: O2 sensing and cancer. Nat Rev Cancer 2008; 8 (11): 865–873. doi: 10.1038/nrc2502.

3. Richter I, Dvořák J. Treatment of metastatic renal cell carcinoma. Klin Onkol 2018; 31 (2): 110–116. doi: 10.14735/amko2018110.

4. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Eng J Med 2007; 356 (2): 115–124. doi: 10.1056/NEJMoa065044.

5. Motzer RJ, Hutson TE, Cella D et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 2013; 369 (8): 722–731. doi: 10.1056/NEJMoa1303989.

6. Motzer RJ, Penkov K, Haanen J et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Eng J Med 2019; 380 (12): 1103–1115. doi: 10.1056/NEJMoa1816047.

7. Rini BI, Plimack ER, Stus V et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Eng J Med 2019; 380 (12): 1116–1127. doi: 10.1056/NEJMoa1816714.

8. Choueiri TK, Escudier B, Powles T et al. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015; 373 (19): 1814–1823. doi: 10.1056/NEJMoa1510016.

9. Motzer RJ, Tannir NM, McDermott DF et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 2018; 378 (14): 1277–1290. doi: 10.1056/NEJMoa1712126.

10. Heng DY, Xie W, Regan MM et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results form a large, multicenter study. J Clin Oncol 2009; 27 (34): 5794–5799. doi: 10.1200/JCO.2008.21.4809.

11. Plana D, Palmer AC, Sorger PK. Independent drug action in combination therapy: implications for precision oncology. Cancer Discov 2022; 12 (3): 606–624. doi: 10.1158/2159-8290.CD-21-0212.

12. Yakes FM, Chen J, Tan J et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresse metastasis, angiogenesis, and tumor growth. Mol Cancer Ther 2011; 10 (12): 2298–2308. doi: 10.1158/1535-7163.MCT-11-0264.

13. Tannir NM, Schwab G, Grunwald V. Cabozantinib: an active novel multikinase inhibitor in renal cell carcinoma. Curr Oncol Rep 2017; 19 (2): 14. doi: 10.1007/s11912-017-0566-9.

14. Zhou L, Liu XD, Sun M et al. Targeting MET and AXL overcomes resistence to sunitinib therapy in renal cell carcinoma. Oncogene 2016; 35 (21): 2687–2697. doi: 10.1038/onc.2015.343.

15. Choueiri TK, Halabi S, Sanford BL et al. Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the alliance A031203 CABOSUN trial. J Clin Oncol 2017; 35 (6): 591–597. doi: 10.1200/JCO.2016.70.7398.

16. Choueiri TK, Powles T, Burotto M et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 2021; 384 (9): 829–841. doi: 10.1056/NEJMoa2026982.

17. Motzer RJ, Powles T, Burotto M et al. Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial. Lancet Oncol 2022; 23 (7): 888–898. doi: 10.1016/S1470-2045 (22) 00290-X.

18. Motzer R, Alekseev B, Rha SY et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med 2021; 384 (14): 1289–1300. doi: 10.1056/NEJMoa2035716.

19. Tannir NM, Albigès L, McDermott DF et al. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial. Ann Oncol 2024; 35 (11): 1026–1038. doi: 10.1016/j.annonc.2024.07.727.